TransMedics Group, Inc. Forecast, price target & analysts
TransMedics Group, Inc. Target price 2026 - Analyst rating & recommendation
TransMedics Group, Inc. Classifications & Recommendation:
TransMedics Group, Inc. Price Target
| Target Price | $151.47 |
| Price | $122.69 |
| Potential |
23.46%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target TransMedics Group, Inc. 2027 .
The average TransMedics Group, Inc. target price is $151.47.
This is
23.46%
register free of charge
$178.50
45.49%
register free of charge
$115.14
6.15%
register free of charge
|
|
| A rating was issued by 20 analysts: 16 Analysts recommend TransMedics Group, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the TransMedics Group, Inc. stock has an average upside potential 2027 of
23.46%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 441.54 | 612.88 |
| 82.74% | 38.81% | |
| EBITDA Margin | 8.54% | 24.17% |
| 3,396.65% | 183.08% | |
| Net Margin | 8.03% | 14.84% |
| 177.52% | 84.78% |
16 Analysts have issued a sales forecast TransMedics Group, Inc. 2025 . The average TransMedics Group, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an TransMedics Group, Inc. EBITDA forecast 2025. The average TransMedics Group, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 TransMedics Group, Inc. Analysts have issued a net profit forecast 2025. The average TransMedics Group, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.01 | 2.66 |
| 231.17% | 163.37% | |
| P/E | 46.07 | |
| EV/Sales | 6.92 |
16 Analysts have issued a TransMedics Group, Inc. forecast for earnings per share. The average TransMedics Group, Inc. EPS is
This results in the following potential growth metrics and future valuations:
TransMedics Group, Inc....
Current TransMedics Group, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Dec 08 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 23 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Oct 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Dec 08 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 23 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Oct 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
